Authors: Eric L Eisenstein Emily F Honeycutt Kevin J Anstrom Richard C Becker Christopher B Granger Sunil V Rao Marc E Jolicoeur E Magnus Ohman for the CATCH Investigators
Publish Date: 2009/01/10
Volume: 34, Issue: 3, Pages: 379-386
Abstract
Thrombocytopenia is associated with increased patient risk However the costs of this complication are not well defined This study assessed the impact of thrombocytopenia on inhospital costs using results from CATCH an observational study that examined 1988 consecutive patients receiving prolonged heparin therapy ≥96 h Thrombocytopenia was defined as group 1 an absolute reduction in platelet count to 150 × 109/L group 2 a relative reduction in platelet count of 50 from admission levels or group 3 both criteria We found that the development of thrombocytopenia was associated with significantly higher total inhospital costs for all groups group 1 difference 8222 95 CI 5020–11425 P 001 group 2 difference 15429 95 CI 7472–23385 P 001 and group 3 difference 27077 95 CI 22901–31252 P 001 However in our adjusted model longer lengthsofstay and greater use of blood transfusions accounted for most incremental inhospital cost differences
Keywords: